US4778054A - Pack for administering medicaments to patients - Google Patents

Pack for administering medicaments to patients Download PDF

Info

Publication number
US4778054A
US4778054A US06/936,148 US93614886A US4778054A US 4778054 A US4778054 A US 4778054A US 93614886 A US93614886 A US 93614886A US 4778054 A US4778054 A US 4778054A
Authority
US
United States
Prior art keywords
pack
container
powder
medicament
blister
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/936,148
Inventor
Robert E. Newell
Robert A. Fitzsimmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838314307A external-priority patent/GB8314307D0/en
Priority claimed from US06/540,203 external-priority patent/US4627432A/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Assigned to GLAXO GROUP LIMITED reassignment GLAXO GROUP LIMITED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: FITZSIMMONS, ROBERT A., NEWELL, ROBERT E.
Application granted granted Critical
Publication of US4778054A publication Critical patent/US4778054A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0003Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6063Optical identification systems
    • A61M2205/6081Colour codes

Definitions

  • This invention relates to a medicament-containing pack for use in a device by means of which the medicament can be administered to or by patients inhaling through the device.
  • the medicament is in powder form.
  • Devices are now quite well known for administering medicaments contained in capsules to patients suffering from bronchial conditions such as, for example, bronchial asthma. It is well known for medicament in powder or other finely divided form to be supplied in capsules which are loaded by a patient into such a device. The medicament is then released from the capsule and inhaled by the patient, usually through the mouth, but sometimes through the nose.
  • capsules which are made of gelatin
  • Gelatin is relatively unstable and is lacking in physical strength so that the capsules need to be protected by packaging, for example in glass bottles.
  • Environmental degradation of both the capsules and their contents may occur in a relatively short time.
  • An object of the present invention is to provide a more convenient way of administering medicament to such patients than has been possible hitherto and which avoids the need to pack medicaments in capsules.
  • the present invention preferably makes use of the technique of packing medicaments by loading them in blister packs, that is to say packs comprising a-sheet, which may be laminated, of foil or plastics material which acts as a carrier and which is provided with a number of breakable or openable containers called "blisters" incorporating a sheet secured on a first sheet to form a cover or lid.
  • blister packs are in common use with tablets of one kind or another, but we have discovered that they can also be used with medicaments in powder form.
  • a pack comprising a circular carrier disc which has a plurality of pre-filled, hermetically sealed containers formed integrally therewith and arranged in a circle, each container containing directly a dose of medicament in the form of a powder, each container being puncturable to form a hole on each side thereof to allow air to flow through the container to entrain the powder contained therein.
  • the invention is suitable for administering a variety of medicaments such as, for example, salbutamol, beclomethasone dipropionate and sodium cromoglycate.
  • FIG. 1 is an exploded perspective view of a first embodiment of the device
  • FIG. 2 is a detailed view of a plunger device of the same device
  • FIG. 3 is an elevation of another embodiment of the device
  • FIG. 4 is an exploded view of the embodiment illustrated in FIG. 3;
  • FIG. 5 is a perspective view of yet another device
  • FIG. 6 is a plan view of a blister pack according to the invention.
  • FIG. 7 is a vertical section through a single blister, before puncturing
  • FIGS. 8 and 9 are vertical sections, not to scale, through part of two packs according to the invention, showing examples of materials which may be used;
  • FIGS. 10 and 11 are vertical sections, on an enlarged scale, showing blisters after puncturing, in which powder has been trapped;
  • FIGS. 12a and 12b are vertical sections, on an enlarged scale showing a blister before and after puncturing.
  • FIG. 13 is a vertical section, on an enlarged scale, showing a blister filled to two different extents with powder.
  • FIGS. 1 and 2 of the drawings comprises a shallow cylindrical housing 1 of a plastics material which has a cylindrical chamber 2 therein.
  • the chamber is closed at one end 3, herein considered the bottom of the chamber, and a removable cover 4 is a close fit over the chamber at the other end.
  • a mouthpiece outlet 5 projects outwardly from the cylindrical wall of the housing 1 and communicates with the interior of the chamber 2.
  • a perforated guard is provided in the mouthpiece to prevent any solid particles of an undesirably large size being inhaled by a patient inhaling through the mouthpiece.
  • a rim or shoulder 6 runs round the inside wall of the chamber 2 to provide an annular support on which a blister pack 7 may be located.
  • the blister pack has a plurality of puncturable containers or "blisters" 8 arranged in a circle.
  • the blisters 8 are filled with medicament in the form of a powder.
  • the blister pack is of circular disc form, and is removably fitted inside the chamber so that it is replaceable when the individual doses of medicament contained in the blisters have been discharged.
  • the blister pack 7 is preferably a circular disc of foil laminate material with blisters or containers 8. Further details of the blister pack are given in the ensuing description.
  • the chamber 2 contains a central open cylindrical support column 9 upstanding from the bottom wall 3 of the chamber.
  • a clamp disc member 10 is removably fitted inside the chamber 2 and is rotatable therein. In use, the clamp member is placed on top of a blister pack 7 which has already been loaded into the chamber and is located on the support shoulder 6.
  • the clamp member 10 has a plurality of apertures 11 which are arranged in a circle and so spaced from each other that each of them will receive one of the blisters 8 of the blister pack 7.
  • a knob 12 is upstanding from the clamp member 10 and when the lid 4 is fitted on the housing 1 the knob 12 will project through an aperture 13 in the top of the lid 4. This knob can be turned by the patient to rotate the clamp member 10 and since the blisters 8 of the blister pack 7 are located in the apertures 11 in the clamp plate 10 rotation of the clamp member will also rotate the blister pack.
  • a plurality of protuberances or pips 14 are provided on the top of the clamp member 10 and engage in a recess 15, FIG. 2, on the underside of the cover 4 to make sure that the clamp plate is correctly aligned in position. As will be seen, the knob 12 is fluted to provide a better grip for the patient.
  • the cover 4 also has an aperture 16 in which a plunger 17 contained in a plunger housing 18 can be received.
  • the plunger has an annular shoulder 19 and a spring 20 can bear between the shoulder 19 and the bottom of the plunger housing 18 to urge the plunger into an upper or inoperative position.
  • the plunger may be provided with a knife edge 21 or other means to enable the blister to be punctured more easily.
  • the plunger it is not essential that the plunger have a knife 21 to puncture the blister. If desired a needle can be used to puncture the blister or the plunger may have a pointed end or even a blunt end or any other convenient puncturing means may be used.
  • the mouthpiece cover can have a locking member (not shown) which can be engaged with the plunger when the device is not in use to prevent accidental actuation of the plunger.
  • the patient needing a dose of medicament may hold the device with the mouthpiece in his mouth.
  • the patient then depresses the plunger to puncture the blister and give access to the medicament therefrom and inhales through the mouthpiece so that the medicament will be entrained in the air flow and will enter the lungs of the patient.
  • the mouthpiece can be provided with air inlet slots 25 to modify the air flow as the patient inhales.
  • the underside of the blister pack can be supported on another clamp plate instead of the support rim or shoulder 6.
  • the blister pack is conveniently arranged to provide a sufficient number of individual doses for a patient for use during a convenient period such as one day or more.
  • the housing can be modified by providing an additional chamber, not visible, at the bottom, this additional chamber being closed by a removable cover 26. This additional chamber can be used to store replacement blister packs.
  • the mouthpiece may, if desired, be arranged so that a patient may use it to inhale through the nose.
  • FIGS. 3 and 4 A modified device which does not use the clamp member 10 is illustrated in FIGS. 3 and 4.
  • the device of this modification comprises a housing 30 having a chamber 31 therein.
  • a mouthpiece 32 projects outwardly from the cylindrical wall of the housing 30 in a generally radial direction and communicates with the interior of the chamber 31.
  • a perforated guard 33 is provided at the entrance to the mouthpiece 32.
  • a rim or shoulder 34 runs round the inside wall of the chamber 31 to provide an annular support for a support member 35 in the form of a circular plate or disc.
  • This support member is arranged to receive a blister pack 36.
  • the blister pack 36 has a plurality of puncturable containers 37 arranged-in a circular row.
  • These containers are in the form of "blisters" of a generally conical form and contain a medicament as described with reference to FIG. 1.
  • the support member 35 has a plurality of holes 38 equal in number to the number of blisters 37 of the blister pack 36.
  • the conical portion of one blister 37 is located in each of the holes 38 when the device is loaded and in use.
  • An external rotatable member 39 with a knurled edge 40 is located in face contact with the bottom of the housing 30.
  • a spindle or the like 41 with radial projections 42 extends centrally from the support member 35 through a hole 43 in the bottom of the housing 30 and into an opening 44 of complementary shape in a spigot 45 of the member 39.
  • a removable cover 46 fits on top of the housing 30.
  • An opening 47 is provided in the cover 46 and engages a projection 48 in the housing 30 so as correctly to locate the cover.
  • the cover 46 carries a bracket 49 on which a lever or trigger 50 is pivotally mounted.
  • a plunger 51 is located on the lever or trigger 50 and extends through a hole 52 in the cover.
  • a spring 53 is provided to bear between the trigger or lever 50 and the top of the cover 46 to urge the lever or trigger upwards.
  • the hole 52 is so positioned that each hole 38 in the support member 35 will register with this hole as the support member 35 is rotated.
  • the trigger 50 can be depressed so that its plunger 51, which may be in the form of a needle, will pierce through the blister 37 located in that hole (i.e. pierce the top and the bottom of the blister) thereby to permit powder to exit from the blister. Some powder will fall into a tray-like compartment 54 inside the chamber 31.
  • the mouthpiece 32 can be enclosed in a mouthpiece cover or sheath 55 which has a channel-like extension 56 which will engage with the bracket 49 to prevent the plunger 51 being depressed to enter through the hole 37.
  • FIG. 5 illustrates a modified device which can conveniently be used to administer two different medicaments to a patient at separate times. Treatment of certain patients does require that they inhale two different kinds of medicament.
  • a common housing 57 contains two chambers equivalent to the chamber 2 of the embodiment illustrated in FIGS. 1 and 2 or to the chamber 31 of the embodiment illustrated in FIGS. 3 and 4. These two chambers are enclosed by removable covers 58 and blister packs contained in the chambers can be rotated in the manner previously described by rotation of knurled wheels, knobs or other members 59.
  • Outlet mouthpieces 60 project outwardly from the common housing 57, each one of these outlets 60 leading into one of the chambers enclosed by the common housing.
  • Trigger mechanisms 61 are provided to enable the blisters of the blister packs contained in the chambers to be pierced so that the contents thereof can be inhaled by the patient.
  • FIGS. 6 and 7 show a blister pack 90 which is circular in plan view, and has a plurality of blisters 91, in this case eight such blisters, to contain powdered medicament.
  • the blisters are each circular in plan view and are arranged in a circle, so as to give a blister pack of the same general appearances as the blister pack 7 in FIG. 1 and the blister pack 36 in FIG. 4.
  • Each blister has a diameter D and a depth d. The values which D and d should have are discussed further below.
  • the diameter of the blister pack itself in this case is 54 mm.
  • the smallest distance between adjacent blisters and between any given blister and the outer edge of the blister pack is preferably at least 3 mm in order to provide an adequate seal between the base and lid film which form the blister pack (see below).
  • the blister pack 90 is formed from a base laminate to which is secured a lid laminate in which the blisters 91 are formed.
  • the example shown in FIG. 8 comprises a base laminate 100, and a lid laminate 110 in which are formed the blisters 91 of which part of one is shown.
  • the blisters each contain powdered medicament 112.
  • the base laminate comprises three principal layers, namely a layer 101 of polyvinyl chloride 100 microns thick which forms one internal surface of each of the blisters and must thus be inert to the medicament 112, a layer 102 of aluminum foil 40 microns thick, and a layer 103 of biaxially oriented polyamide 25 microns thick.
  • the layers are secured to one another by layers of adhesive 104 and 105.
  • a fourth principal layer 106 may be added, namely a further layer of biaxially oriented polyamide 20 microns thick. This is secured to the layer 103 by an adhesive layer 107.
  • the lid laminate 110 comprises a layer 118 of heat seal lacquer applied at a rate of 9 g/m 2 which forms an internal surface of each of the blisters and must thus be inert with respect to the medicament 112, a layer 114 of aluminum 25 microns thick and a layer 115 of a polyester lacquer applied at a rate of 2-10 g/m 2 .
  • the lacquer layer 115 can be coloured, for decorative purposes and/or to assist the patient in identifying the medicament, and can also carry printing, for example further identification and/or instructions for use.
  • the base and lid laminates are impermeable to light, air water and water vapor, and microorganisms, and the heat seal which the lacquer layer 113 forms with the PVC layer 101 is likewise impermeable, so that the medicament 112 is completely protected.
  • FIG. 9 shows alternative materials which may be used.
  • the blister pack of FIG. 9 comprises a base laminate 120 and a lid laminate 130.
  • the base laminate comprises a polyethylene layer 121 applied at a rate of 20 g/m 2 and an aluminum layer 122 which is 20 microns thick. In the manufacture of the base laminate the polyethylene is extruded on to the aluminum.
  • the base laminate 120 further comprises a layer 123 of oriented polyamide 25 microns thick secured to the layer 122 by an adhesive layer 124.
  • the lid laminate 180 which is heat sealed to the base laminate, comprises a layer 181 of polyethylene applied at a rate of 15 g/m 2 extruded on to a layer 132 of aluminum 25 microns thick, and a layer 133 of polyester lacquer applied at a rate of 2-10 gm/m 2 .
  • the lacquer layer 188 serves the same purpose as the lacquer layer 115 in the embodiment of FIG. 8.
  • the embodiment of FIG. 9 has basically the same impermeability characteristics as those of FIG. 8.
  • laminates shown in FIGS. 8 and 9 are examples only of structures which may be used in the present invention.
  • Laminates of the type shown in FIGS. 8 and 9 are available from Aluminum-Walzwerke Singen GmbH of Alusingen-Platz 1, D-7700 Singen/Hohentwiel, West Germany.
  • One feature of the embodiments of FIGS. 8 and 9 is that they are relatively rigid, which helps to avoid them being damaged and makes it easier to use them in the devices shown in FIGS. 1 to 5.
  • the powdered medicament in the blisters preferably has a particle size range of from 0.5 to 10 microns.
  • the medicament may comprise a pharmacologically active substance, such as one or more of those mentioned above, with a pharmaceutically acceptable carrier, such as lactose or starch, in powder form.
  • the total amount of medicament present in each blister is preferably from 20-50 mg.
  • This quantity of powder is such that it can be inhaled by an adult patient by a single inhalation.
  • the internal volume of each blister is preferably such that the medicament occupies only a relatively small proportion of the volume. The reason for this is to enable the blister to be emptied as completely as possible and as reproducibly as possible, the latter being important to ensure that the patient always receives substantially the same dose.
  • this amount can be kept to as little as 10% of the original contents of the blister, or even less.
  • FIG. 10 shows, after puncturing a blister 91 which was overfilled with medicament, i.e. the medicament occupied too great a proportion of the volume.
  • the peripheral portion of the punctured cover has trapped some of the powder in an annular region 140.
  • FIG. 11 shows powder entrapment produced by having a blister which is too shallow, i.e. the ratio of diameter to depth is too great.
  • the peripheral portion of the punctured cover traps powder in an annular region 150.
  • FIGS. 12a and 12b show a blister, before and after puncturing respectively, which is neither overfilled nor too shallow.
  • no powder is shown trapped in the region 160 which corresponds to the regions 140 and 150. In practice, a little powder may be trapped even in this case, but the amount will be small compared to that in regions 140 and 150.
  • FIG. 13 indicates the filling range which is preferred in order to reduce powder entrapment caused by the mechanism of FIG. 10, whilst at the same time having enough powder to give a reproducible dose.
  • the right hand side of FIG. 13 indicates the maximum degree of filling which may be used without significant powder entrapment.
  • the internal depth of the blister (d in FIG. 7) is 4.5 mm and its volume is 0.2 cm 3 .
  • the blister contains 40 mg of powder having a bulk density of 0.5 and thus occupying a volume of 0.08 cm 3 (40% of the blister volume).
  • the clearance c between the upper surface of the powder and the blister cover is 2.8mm, i.e. the depth of the powder is approximately half the depth of the blister.
  • the blister contains 25 mg of powder occupying 0.5 cm 3 (25% of the blister volume), and the clearance c is 2.8 mm. As a practical matter there should preferably be at least 20 mg of powder.
  • the ratio of blister diameter D to blister depth d (see FIG. 7) is preferably less than 4.5:1. Typical values which may desirably be used are in the region of 2.6:1 to 2.9 to 1. The ratio is preferably not less than 2.4:1 in order to avoid problems in forming the blisters. Values of D are typically about 11 to 12 mm, and values for d are typically about 3.8 to 4.5 mm.
  • the generally conical shape of the blisters is advantageous in that it presents the medicament to the airflow through the punctured blister in such a way as to assist emptying by the airflow.

Abstract

A pack is provided comprising a circular carrier disc provided with a plurality of containers arranged in a circle and each containing a dose of medicament in particulate form. The containers are puncturable to permit the medicament therein to be released.

Description

RELATED APPLICATION
This application is a continuation-in-part of U.S. Ser. No. 540,203 filed 10/07/83 and now U.S. Pat. No. 4,627,432 entitled "Devices for Administering Medicaments to Patients".
FIELD OF THE INVENTION
This invention relates to a medicament-containing pack for use in a device by means of which the medicament can be administered to or by patients inhaling through the device. The medicament is in powder form.
BACKGROUND OF THE INVENTION
Devices are now quite well known for administering medicaments contained in capsules to patients suffering from bronchial conditions such as, for example, bronchial asthma. It is well known for medicament in powder or other finely divided form to be supplied in capsules which are loaded by a patient into such a device. The medicament is then released from the capsule and inhaled by the patient, usually through the mouth, but sometimes through the nose.
The specifications of PCT Application Publication No. WO82/01470 and U.K. Patent Specification No. 1387954 both describe devices for dispensing medicament in powder form from capsules. In each of these previously described devices, the capsules are mounted on a rotatable support member on which each capsule in turn can be brought to a position in which it is opened to enable medicament to exit from the capsule to permit it to be inhaled by a patient inhaling through a mouthpiece of the device. In the device described in U.K. Specification No. 1387954, the capsules may be mounted in a so-called blister pack.
There are disadvantages in the use of capsules, which are made of gelatin, to contain medicaments. Gelatin is relatively unstable and is lacking in physical strength so that the capsules need to be protected by packaging, for example in glass bottles. Environmental degradation of both the capsules and their contents may occur in a relatively short time.
BRIEF SUMMARY OF THE INVENTION
An object of the present invention is to provide a more convenient way of administering medicament to such patients than has been possible hitherto and which avoids the need to pack medicaments in capsules. The present invention preferably makes use of the technique of packing medicaments by loading them in blister packs, that is to say packs comprising a-sheet, which may be laminated, of foil or plastics material which acts as a carrier and which is provided with a number of breakable or openable containers called "blisters" incorporating a sheet secured on a first sheet to form a cover or lid. Such blister packs are in common use with tablets of one kind or another, but we have discovered that they can also be used with medicaments in powder form.
According to the present invention there is provided a pack comprising a circular carrier disc which has a plurality of pre-filled, hermetically sealed containers formed integrally therewith and arranged in a circle, each container containing directly a dose of medicament in the form of a powder, each container being puncturable to form a hole on each side thereof to allow air to flow through the container to entrain the powder contained therein.
The invention is suitable for administering a variety of medicaments such as, for example, salbutamol, beclomethasone dipropionate and sodium cromoglycate.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying schematic drawings show some devices in which a pack according to the invention may be used, as well as the pack itself.
FIG. 1 is an exploded perspective view of a first embodiment of the device;
FIG. 2 is a detailed view of a plunger device of the same device;
FIG. 3 is an elevation of another embodiment of the device;
FIG. 4 is an exploded view of the embodiment illustrated in FIG. 3;
FIG. 5 is a perspective view of yet another device;
FIG. 6 is a plan view of a blister pack according to the invention;
FIG. 7 is a vertical section through a single blister, before puncturing;
FIGS. 8 and 9 are vertical sections, not to scale, through part of two packs according to the invention, showing examples of materials which may be used;
FIGS. 10 and 11 are vertical sections, on an enlarged scale, showing blisters after puncturing, in which powder has been trapped;
FIGS. 12a and 12b are vertical sections, on an enlarged scale showing a blister before and after puncturing; and
FIG. 13 is a vertical section, on an enlarged scale, showing a blister filled to two different extents with powder.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The device illustrated in FIGS. 1 and 2 of the drawings comprises a shallow cylindrical housing 1 of a plastics material which has a cylindrical chamber 2 therein. The chamber is closed at one end 3, herein considered the bottom of the chamber, and a removable cover 4 is a close fit over the chamber at the other end.
A mouthpiece outlet 5 projects outwardly from the cylindrical wall of the housing 1 and communicates with the interior of the chamber 2. A perforated guard, not shown, is provided in the mouthpiece to prevent any solid particles of an undesirably large size being inhaled by a patient inhaling through the mouthpiece.
A rim or shoulder 6 runs round the inside wall of the chamber 2 to provide an annular support on which a blister pack 7 may be located. The blister pack has a plurality of puncturable containers or "blisters" 8 arranged in a circle. The blisters 8 are filled with medicament in the form of a powder.
The blister pack is of circular disc form, and is removably fitted inside the chamber so that it is replaceable when the individual doses of medicament contained in the blisters have been discharged. The blister pack 7 is preferably a circular disc of foil laminate material with blisters or containers 8. Further details of the blister pack are given in the ensuing description.
The chamber 2 contains a central open cylindrical support column 9 upstanding from the bottom wall 3 of the chamber. A clamp disc member 10 is removably fitted inside the chamber 2 and is rotatable therein. In use, the clamp member is placed on top of a blister pack 7 which has already been loaded into the chamber and is located on the support shoulder 6.
The clamp member 10 has a plurality of apertures 11 which are arranged in a circle and so spaced from each other that each of them will receive one of the blisters 8 of the blister pack 7. A knob 12 is upstanding from the clamp member 10 and when the lid 4 is fitted on the housing 1 the knob 12 will project through an aperture 13 in the top of the lid 4. This knob can be turned by the patient to rotate the clamp member 10 and since the blisters 8 of the blister pack 7 are located in the apertures 11 in the clamp plate 10 rotation of the clamp member will also rotate the blister pack. A plurality of protuberances or pips 14 are provided on the top of the clamp member 10 and engage in a recess 15, FIG. 2, on the underside of the cover 4 to make sure that the clamp plate is correctly aligned in position. As will be seen, the knob 12 is fluted to provide a better grip for the patient.
The cover 4 also has an aperture 16 in which a plunger 17 contained in a plunger housing 18 can be received. The plunger has an annular shoulder 19 and a spring 20 can bear between the shoulder 19 and the bottom of the plunger housing 18 to urge the plunger into an upper or inoperative position. The plunger may be provided with a knife edge 21 or other means to enable the blister to be punctured more easily. When the plunger 17 is depressed against the action of the spring 20, the lower edge portion 21 of the plunger will pass through an aperture 22 in the plunger housing to pass through a blister 8 located in register with the plunger. Such engagement will puncture the blister, forming a hole on both sides thereof. This action will so open the blister that when a patient inhales air will pass through the blister, the medicament being entrained in the air flow and exiting through the mouthpiece 5 via a transfer cavity 23 inside the chamber in communication with the mouthpiece 5. By rotation of the knob 12 the clamp member 10 and the blister pack 7 can be rotated to bring each blister in turn into location beneath the plunger. The various protuberances or pips 14 will in turn engage in the recess 15 to make sure that the blister pack is correctly registered with the plunger.
It is not essential that the plunger have a knife 21 to puncture the blister. If desired a needle can be used to puncture the blister or the plunger may have a pointed end or even a blunt end or any other convenient puncturing means may be used.
The mouthpiece cover can have a locking member (not shown) which can be engaged with the plunger when the device is not in use to prevent accidental actuation of the plunger.
In use, the patient needing a dose of medicament may hold the device with the mouthpiece in his mouth. The patient then depresses the plunger to puncture the blister and give access to the medicament therefrom and inhales through the mouthpiece so that the medicament will be entrained in the air flow and will enter the lungs of the patient. If desired, the mouthpiece can be provided with air inlet slots 25 to modify the air flow as the patient inhales.
In a modification not illustrated the underside of the blister pack can be supported on another clamp plate instead of the support rim or shoulder 6.
The blister pack is conveniently arranged to provide a sufficient number of individual doses for a patient for use during a convenient period such as one day or more. The housing can be modified by providing an additional chamber, not visible, at the bottom, this additional chamber being closed by a removable cover 26. This additional chamber can be used to store replacement blister packs.
The mouthpiece may, if desired, be arranged so that a patient may use it to inhale through the nose.
A modified device which does not use the clamp member 10 is illustrated in FIGS. 3 and 4. The device of this modification comprises a housing 30 having a chamber 31 therein. A mouthpiece 32 projects outwardly from the cylindrical wall of the housing 30 in a generally radial direction and communicates with the interior of the chamber 31. A perforated guard 33 is provided at the entrance to the mouthpiece 32. A rim or shoulder 34 runs round the inside wall of the chamber 31 to provide an annular support for a support member 35 in the form of a circular plate or disc. This support member is arranged to receive a blister pack 36. The blister pack 36 has a plurality of puncturable containers 37 arranged-in a circular row. These containers are in the form of "blisters" of a generally conical form and contain a medicament as described with reference to FIG. 1. The support member 35 has a plurality of holes 38 equal in number to the number of blisters 37 of the blister pack 36. The conical portion of one blister 37 is located in each of the holes 38 when the device is loaded and in use. An external rotatable member 39 with a knurled edge 40 is located in face contact with the bottom of the housing 30. A spindle or the like 41 with radial projections 42 extends centrally from the support member 35 through a hole 43 in the bottom of the housing 30 and into an opening 44 of complementary shape in a spigot 45 of the member 39. The spigot 45 passes through the hole 43 and the spindle 41 and 42 engages in the opening 44 so that rotation of the member 39 will cause similar rotation to the support member 35. A removable cover 46 fits on top of the housing 30. An opening 47 is provided in the cover 46 and engages a projection 48 in the housing 30 so as correctly to locate the cover. The cover 46 carries a bracket 49 on which a lever or trigger 50 is pivotally mounted. A plunger 51 is located on the lever or trigger 50 and extends through a hole 52 in the cover. A spring 53 is provided to bear between the trigger or lever 50 and the top of the cover 46 to urge the lever or trigger upwards.
The hole 52 is so positioned that each hole 38 in the support member 35 will register with this hole as the support member 35 is rotated.
When one of the holes 38 is in register with the hole 52 the trigger 50 can be depressed so that its plunger 51, which may be in the form of a needle, will pierce through the blister 37 located in that hole (i.e. pierce the top and the bottom of the blister) thereby to permit powder to exit from the blister. Some powder will fall into a tray-like compartment 54 inside the chamber 31. When the patient inhales, air passes through the pierced blister so that powder will be entrained in the airflow and will, with powder from the compartment 54, be withdrawn through the guard 33 and the mouthpiece 32. When the device is not in use, the mouthpiece 32 can be enclosed in a mouthpiece cover or sheath 55 which has a channel-like extension 56 which will engage with the bracket 49 to prevent the plunger 51 being depressed to enter through the hole 37.
When the device is in use and the patient inhales through the mouthpiece 32 it is, of course, essential for air to be able to enter the interior of the chamber 31. Any suitable air inlets can be provided. Conveniently, however, air can enter through the hole 52 the plunger or needle 51 being smaller in diameter than the diameter of the hole 52 so that it serves as an air inlet.
FIG. 5 illustrates a modified device which can conveniently be used to administer two different medicaments to a patient at separate times. Treatment of certain patients does require that they inhale two different kinds of medicament. In the device illustrated in FIG. 5, a common housing 57 contains two chambers equivalent to the chamber 2 of the embodiment illustrated in FIGS. 1 and 2 or to the chamber 31 of the embodiment illustrated in FIGS. 3 and 4. These two chambers are enclosed by removable covers 58 and blister packs contained in the chambers can be rotated in the manner previously described by rotation of knurled wheels, knobs or other members 59. Outlet mouthpieces 60 project outwardly from the common housing 57, each one of these outlets 60 leading into one of the chambers enclosed by the common housing. Trigger mechanisms 61 are provided to enable the blisters of the blister packs contained in the chambers to be pierced so that the contents thereof can be inhaled by the patient.
More details of the blister packs which may be used will now be given, with reference to FIGS. 6 to 13 of the accompanying drawings.
FIGS. 6 and 7 show a blister pack 90 which is circular in plan view, and has a plurality of blisters 91, in this case eight such blisters, to contain powdered medicament. The blisters are each circular in plan view and are arranged in a circle, so as to give a blister pack of the same general appearances as the blister pack 7 in FIG. 1 and the blister pack 36 in FIG. 4. Each blister has a diameter D and a depth d. The values which D and d should have are discussed further below. The diameter of the blister pack itself in this case is 54 mm. The smallest distance between adjacent blisters and between any given blister and the outer edge of the blister pack is preferably at least 3 mm in order to provide an adequate seal between the base and lid film which form the blister pack (see below).
The blister pack 90 is formed from a base laminate to which is secured a lid laminate in which the blisters 91 are formed. The example shown in FIG. 8 comprises a base laminate 100, and a lid laminate 110 in which are formed the blisters 91 of which part of one is shown. The blisters each contain powdered medicament 112. The base laminate comprises three principal layers, namely a layer 101 of polyvinyl chloride 100 microns thick which forms one internal surface of each of the blisters and must thus be inert to the medicament 112, a layer 102 of aluminum foil 40 microns thick, and a layer 103 of biaxially oriented polyamide 25 microns thick. The layers are secured to one another by layers of adhesive 104 and 105. As indicated by broken lines, a fourth principal layer 106 may be added, namely a further layer of biaxially oriented polyamide 20 microns thick. This is secured to the layer 103 by an adhesive layer 107. The lid laminate 110 comprises a layer 118 of heat seal lacquer applied at a rate of 9 g/m2 which forms an internal surface of each of the blisters and must thus be inert with respect to the medicament 112, a layer 114 of aluminum 25 microns thick and a layer 115 of a polyester lacquer applied at a rate of 2-10 g/m2. The lacquer layer 115 can be coloured, for decorative purposes and/or to assist the patient in identifying the medicament, and can also carry printing, for example further identification and/or instructions for use.
The base and lid laminates are impermeable to light, air water and water vapor, and microorganisms, and the heat seal which the lacquer layer 113 forms with the PVC layer 101 is likewise impermeable, so that the medicament 112 is completely protected.
FIG. 9 shows alternative materials which may be used. The blister pack of FIG. 9 comprises a base laminate 120 and a lid laminate 130. The base laminate comprises a polyethylene layer 121 applied at a rate of 20 g/m2 and an aluminum layer 122 which is 20 microns thick. In the manufacture of the base laminate the polyethylene is extruded on to the aluminum. The base laminate 120 further comprises a layer 123 of oriented polyamide 25 microns thick secured to the layer 122 by an adhesive layer 124. The lid laminate 180, which is heat sealed to the base laminate, comprises a layer 181 of polyethylene applied at a rate of 15 g/m2 extruded on to a layer 132 of aluminum 25 microns thick, and a layer 133 of polyester lacquer applied at a rate of 2-10 gm/m2. The lacquer layer 188 serves the same purpose as the lacquer layer 115 in the embodiment of FIG. 8. The layers 121 and 131 of polyethylene from the internal surfaces of the powder-containing blisters and are inert with respect to the powder. The embodiment of FIG. 9 has basically the same impermeability characteristics as those of FIG. 8.
It should be noted that the laminates shown in FIGS. 8 and 9 are examples only of structures which may be used in the present invention. Laminates of the type shown in FIGS. 8 and 9 are available from Aluminum-Walzwerke Singen GmbH of Alusingen-Platz 1, D-7700 Singen/Hohentwiel, West Germany. One feature of the embodiments of FIGS. 8 and 9 is that they are relatively rigid, which helps to avoid them being damaged and makes it easier to use them in the devices shown in FIGS. 1 to 5.
It should also be noted that the seal between the lid and base laminates cannot be broken and resealed without it being evident that this has occurred so that tamper evidence is provided. This type of tamper evidence is not provided by the capsules which are conventionally used.
The powdered medicament in the blisters preferably has a particle size range of from 0.5 to 10 microns. The medicament may comprise a pharmacologically active substance, such as one or more of those mentioned above, with a pharmaceutically acceptable carrier, such as lactose or starch, in powder form.
The total amount of medicament present in each blister, including any carrier, is preferably from 20-50 mg. This quantity of powder is such that it can be inhaled by an adult patient by a single inhalation. The internal volume of each blister is preferably such that the medicament occupies only a relatively small proportion of the volume. The reason for this is to enable the blister to be emptied as completely as possible and as reproducibly as possible, the latter being important to ensure that the patient always receives substantially the same dose. As will now be explained with reference to FIGS. 10 to 13, although some powder may be left behind in the blister and not entrained by the air flow, by proper design of the blister this amount can be kept to as little as 10% of the original contents of the blister, or even less.
FIG. 10 shows, after puncturing a blister 91 which was overfilled with medicament, i.e. the medicament occupied too great a proportion of the volume. As can be seen, the peripheral portion of the punctured cover has trapped some of the powder in an annular region 140. FIG. 11 shows powder entrapment produced by having a blister which is too shallow, i.e. the ratio of diameter to depth is too great. Here the peripheral portion of the punctured cover traps powder in an annular region 150. FIGS. 12a and 12b, in contrast, show a blister, before and after puncturing respectively, which is neither overfilled nor too shallow. Here no powder is shown trapped in the region 160 which corresponds to the regions 140 and 150. In practice, a little powder may be trapped even in this case, but the amount will be small compared to that in regions 140 and 150.
FIG. 13 indicates the filling range which is preferred in order to reduce powder entrapment caused by the mechanism of FIG. 10, whilst at the same time having enough powder to give a reproducible dose. The right hand side of FIG. 13 indicates the maximum degree of filling which may be used without significant powder entrapment. The internal depth of the blister (d in FIG. 7) is 4.5 mm and its volume is 0.2 cm3. The blister contains 40 mg of powder having a bulk density of 0.5 and thus occupying a volume of 0.08 cm3 (40% of the blister volume). The clearance c between the upper surface of the powder and the blister cover is 2.8mm, i.e. the depth of the powder is approximately half the depth of the blister. The left hand side of FIG. 13 illustrates a presently preferred degree of filling. Here the blister contains 25 mg of powder occupying 0.5 cm3 (25% of the blister volume), and the clearance c is 2.8 mm. As a practical matter there should preferably be at least 20 mg of powder. In order to reduce powder entrapment by the mechanism of FIG. 11 the ratio of blister diameter D to blister depth d (see FIG. 7) is preferably less than 4.5:1. Typical values which may desirably be used are in the region of 2.6:1 to 2.9 to 1. The ratio is preferably not less than 2.4:1 in order to avoid problems in forming the blisters. Values of D are typically about 11 to 12 mm, and values for d are typically about 3.8 to 4.5 mm. It should also be noted that the generally conical shape of the blisters is advantageous in that it presents the medicament to the airflow through the punctured blister in such a way as to assist emptying by the airflow.

Claims (15)

I claim:
1. A pack comprising a circular carrier disc which has a plurality of pre-filled, hermetically sealed containers formed integrally therewith and arranged in a circle, each container being of generally conical form and containing a dose of medicament in the form of an inhalable powder, each container comprising at least opposed puncturable surfaces for forming a hole through said container to allow air to flow through the container to entrain the powder contained therein.
2. A pack as claimed in claim 1, wherein the ratio of diameter to depth of each container is less than 4.5:1.
3. A pack as claimed in claim 1, wherein the ratio of diameter to depth of each container is not less than 2.4:1.
4. A pack as claimed in claim 1, wherein the carrier disc is of foil laminate material.
5. A pack as claimed in claim 4, comprising a base laminate and, secured thereto, a lid laminate in which depressions are formed to define the containers with the base laminate.
6. A pack as claimed in claim 5, in which the base laminate and lid laminate are secured to one another by a seal such that breaking and re-sealing thereof is tamper evident.
7. A pack as claimed in claim 5, wherein each of the base and lid laminate includes a layer of aluminum.
8. A pack as claimed in claim 1, wherein the medicament comprises an active ingredient selected from salbutamol and beclomethasone dipropionate.
9. A pack as claimed in claim 1, wherein the medicament comprises sodium cromoglycate.
10. A pack as claimed in claim 1, in which the particle size of the medicament is substantially in the range 0.5-10 microns.
11. A pack as claimed in claim 1, in which the.medicament comprises a pharmacologically active substance admixed with a solid pharmaceutically acceptable carrier.
12. A pack as claimed in claim 1, in which each container has a volume such that the powder therein occupies not more than 40% thereof.
13. A pack as claimed in claim 12, in which the powder occupies approximately 25% thereof.
14. A pack as claimed in claim 1, in which each container contains at least 20 mg of powder.
15. A pack as claimed in claim 1, in which each container has a depth such that the depth of powder therein is not more than approximately half the depth of the container when the container is oriented so that the conical form thereof tapers downwardly.
US06/936,148 1982-10-08 1986-12-01 Pack for administering medicaments to patients Expired - Lifetime US4778054A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB8228887 1982-10-08
GB8228887 1982-10-08
GB838314307A GB8314307D0 (en) 1983-05-24 1983-05-24 Medical administration devices
GB8314307 1983-05-24
US06/540,203 US4627432A (en) 1982-10-08 1983-10-07 Devices for administering medicaments to patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/540,203 Continuation-In-Part US4627432A (en) 1982-10-08 1983-10-07 Devices for administering medicaments to patients

Publications (1)

Publication Number Publication Date
US4778054A true US4778054A (en) 1988-10-18

Family

ID=27261787

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/936,148 Expired - Lifetime US4778054A (en) 1982-10-08 1986-12-01 Pack for administering medicaments to patients

Country Status (1)

Country Link
US (1) US4778054A (en)

Cited By (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009561A (en) * 1989-08-18 1991-04-23 Pharmacia Diagnostics Inc. Reagent tablet dispenser
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5277328A (en) * 1993-05-24 1994-01-11 Tocco Gary A Multiply compartmented cooler
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5348158A (en) * 1991-12-19 1994-09-20 G. D. Searle & Co. Dispenser pack for the successive dispensing of a drug
US5356010A (en) * 1993-01-21 1994-10-18 Primary Delivery Systems, Inc. Container with blister pack opener
US5431283A (en) * 1993-01-21 1995-07-11 Primary Delivery Systems, Inc. Blister pack opener-ejector
US5464118A (en) * 1993-08-11 1995-11-07 Hoechst Aktiengesellschaft Apparatus for removing solid medications from blister packs
US5492112A (en) * 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
WO1996033759A1 (en) * 1995-04-24 1996-10-31 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US5816404A (en) * 1996-02-20 1998-10-06 Seidler; David Blister pack with built-in openers
US5853101A (en) * 1993-01-21 1998-12-29 Primary Delivery Systems, Inc. Blister pack opener
US5857456A (en) * 1996-06-10 1999-01-12 Sarnoff Corporation Inhaler apparatus with an electronic means for enhanced release of dry powders
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5909822A (en) * 1997-05-03 1999-06-08 George; Donald C. Pill dispenser employing a sealed pill carrier
US5915560A (en) * 1997-05-03 1999-06-29 George; Donald C. Compartmentalized pill dispenser
US5921237A (en) * 1995-04-24 1999-07-13 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5964417A (en) * 1996-11-20 1999-10-12 Ing. Erich Pfeiffer Gmbh Dispenser for discharging media
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US6098835A (en) * 1998-09-03 2000-08-08 Valley Design Inc. Child resistant pill rotating disk dispenser
US6116238A (en) * 1997-12-02 2000-09-12 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
WO2001085097A2 (en) * 2000-05-10 2001-11-15 Innovative Devices, Llc Medicament container with same side airflow inlet and outlet and method of use
US6367473B1 (en) * 1997-02-08 2002-04-09 Ing. Erich Pfeiffer Gmbh Medium dispenser
US6443307B1 (en) 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
US20020168322A1 (en) * 1998-10-09 2002-11-14 Andrew Clark Flow resistance modulated aerosolized active agent delivery
WO2002098495A1 (en) 2001-06-07 2002-12-12 Innovata Biomed Limited Unit dosage powder container
US6550477B1 (en) 1995-08-02 2003-04-22 Innovative Devices, Llc Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US20030075172A1 (en) * 2001-10-19 2003-04-24 Johnson Keith A. Method and apparatus for dispensing inhalator medicament
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
WO2003080469A1 (en) * 2002-03-19 2003-10-02 Comar, Inc. Rotatable compact case with non-removable pill package insert
US20030185765A1 (en) * 1992-07-08 2003-10-02 Platz Robert M. Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
WO2003095010A2 (en) * 2002-05-10 2003-11-20 Oriel Therapeutics, Inc. Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material
US6655379B2 (en) 1998-03-16 2003-12-02 Nektar Therapeutics Aerosolized active agent delivery
WO2003107397A2 (en) * 2002-05-15 2003-12-24 Glaxo Group Limited Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging
US20040000309A1 (en) * 2002-06-18 2004-01-01 William Alston Flow regulator for aerosol drug delivery and methods
US6672304B1 (en) 1995-06-08 2004-01-06 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIs)
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US20040050860A1 (en) * 2002-05-10 2004-03-18 Crowder Timothy M. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US6737045B2 (en) 1994-03-07 2004-05-18 Nektar Therapeutics Methods and compositions for the pulmonary delivery insulin
US20040118399A1 (en) * 2002-12-18 2004-06-24 Elan Pharmaceutical Technologies Unit dose dry powder inhaler
US20040153262A1 (en) * 2002-05-10 2004-08-05 Crowder Timothy M. Dry powder dose filling systems and related methods
US20040173211A1 (en) * 2003-01-14 2004-09-09 Boehringer Ingelheim International Gmbh Powder inhaler
US6810872B1 (en) * 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US20040237961A1 (en) * 1995-06-08 2004-12-02 Snow John Medlin Inhalation actuated device for use with metered dose inhalers (MDIs)
US20040250812A1 (en) * 1990-03-02 2004-12-16 Davies Michael Birsha Inhalation device
US6871647B2 (en) 2001-09-19 2005-03-29 Advent Pharmaceuticals Pty Ltd Inhaler
US6881200B2 (en) 1993-04-08 2005-04-19 Powderject Research Limited Needleless syringe using super sonic gas flow for particle delivery
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US20050103678A1 (en) * 2002-03-26 2005-05-19 Clark Verna L. Method for forming a laminate assembly and products formed thereby
US20050143675A1 (en) * 2003-12-31 2005-06-30 Home Diagnostics, Inc. Integrated diagnostic test system
US6915802B1 (en) * 1999-10-16 2005-07-12 Smithkline Beecham Corporation Medicament pack
US20050154491A1 (en) * 2002-01-25 2005-07-14 Anderson Gregor J.M. Medicament dispenser
US20050161041A1 (en) * 2000-05-16 2005-07-28 Carlos Schuler Systems devices and methods for opening receptacles having a powder to be fluidized
US20050236420A1 (en) * 2002-03-06 2005-10-27 Reckitt Benckiser N.V. Container
US20050238708A1 (en) * 2004-04-23 2005-10-27 Andrew Jones Sealed capsule including an integrated puncturing mechanism
US20050251289A1 (en) * 2002-07-25 2005-11-10 Bonney Stanley G Medicament dispenser
US20050247312A1 (en) * 2002-07-25 2005-11-10 Davies Michael B Medicament dispenser
US20050256201A1 (en) * 2002-04-25 2005-11-17 Glaxo Group Limited Phenethanolamine derivatives
US20050268909A1 (en) * 2002-07-25 2005-12-08 Bonney Stanley G Medicament dispenser
US20050268908A1 (en) * 2002-07-25 2005-12-08 Bonney Stanley G Medicament dispenser
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
US20050279349A1 (en) * 1991-07-02 2005-12-22 Patton John S Method and device for delivering aerosolized medicaments
US20060005398A1 (en) * 2004-07-12 2006-01-12 Steve Sramek Device for removing a pharmaceutical dosage unit from a unit package
US20060050765A1 (en) * 2002-04-25 2006-03-09 Walker Dwight S Magnetoacoustic sensor system and associated method for sensing environmental conditions
US20060076010A1 (en) * 2002-12-18 2006-04-13 King Michael L Drug delivery system with vented mouthpiece
US20060148771A1 (en) * 2003-02-14 2006-07-06 Keith Biggadike Medicinal compounds
US20060187750A1 (en) * 2002-03-01 2006-08-24 Victor Aldrich Rotary blending apparatus and system
US20060205790A1 (en) * 2002-10-22 2006-09-14 Coe Diane M Medicinal arylethanolamine compounds
WO2006104889A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Novel compounds
US20060237010A1 (en) * 2003-06-16 2006-10-26 Rijksuniversiteit Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US7159720B2 (en) 2004-03-18 2007-01-09 Pearson Stephen J Container having a rotatable ring
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
US20070053843A1 (en) * 2003-10-28 2007-03-08 Dawson Michelle L Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
US20070066527A1 (en) * 2005-09-07 2007-03-22 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070135490A1 (en) * 2003-10-24 2007-06-14 Keith Biggadike Phenetanolamine derivatives
US20070139442A1 (en) * 2002-09-13 2007-06-21 Robinson Karl E Coated blending system
US20070164029A1 (en) * 2006-01-03 2007-07-19 Gelardi John A System for Opening an Article Encasement
US20070172385A1 (en) * 2003-12-17 2007-07-26 Glaxo Group Limited Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders
US7278419B2 (en) 1993-01-29 2007-10-09 Novo Nordisk A/S Method for treating diabetes mellitus in a patient
US20070267318A1 (en) * 2002-08-29 2007-11-22 Colbert Packaging Corporation Dispensing Package
US20070277820A1 (en) * 2003-10-27 2007-12-06 Timothy Crowder Blister packages and associated methods of fabricating dry powder drug containment systems
US20080042823A1 (en) * 2004-11-12 2008-02-21 Heasley Matthew G Sensor System with Acoustic Transducer
WO2008037519A1 (en) * 2006-09-26 2008-04-03 Alfred Von Schuckmann Dispenser for powder compounds
US20080108645A1 (en) * 2004-02-11 2008-05-08 Cambridge Laboratories, (Ireland), Ltd. Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
US7377277B2 (en) 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
US20080125462A1 (en) * 2005-01-11 2008-05-29 Lois Elizabeth Vernon Cinnamate Salts Of A Beta-2 Adrenergic Agonist
US20080156816A1 (en) * 2007-01-03 2008-07-03 Gelardi John A Container With Cutting Apparatus
US20080197045A1 (en) * 2005-07-27 2008-08-21 Burkhard Metzger Medicament Blister
US20080223747A1 (en) * 2002-08-29 2008-09-18 Colbert Packaging Corporation Childproof, senior-friendly blister pack
US7428446B2 (en) 2002-05-10 2008-09-23 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US20080237082A1 (en) * 2007-03-29 2008-10-02 R. P. Scherer Technologies, Inc. Child resistant device for housing blister packs
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US7451761B2 (en) 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US20080300535A1 (en) * 2001-07-26 2008-12-04 Powderject Research Limited Particle cassette, method and kit therefor
US20080319000A1 (en) * 2005-07-14 2008-12-25 Cambridge Laboratories (Ireland) Limited Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease
WO2009004456A1 (en) * 2007-07-02 2009-01-08 Pfizer Limited Dry powder container and use of such dry powder container in a dry powder inhaler
US20090029901A1 (en) * 2005-02-10 2009-01-29 Marian Wood-Kaczmar Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations
US20090029906A1 (en) * 2005-04-29 2009-01-29 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US20090047351A1 (en) * 2005-02-10 2009-02-19 Stephen Newman Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom
US20090057186A1 (en) * 2005-02-15 2009-03-05 Willard Rick L Pill packaging system
US20090105309A1 (en) * 2003-10-22 2009-04-23 Glaxo Group Limited Medicinal Compounds
US20090149389A1 (en) * 2007-01-10 2009-06-11 Purdue Research Foundation Kinase Inhibitors And Uses Thereof
US20090192227A1 (en) * 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
US20090196927A1 (en) * 2007-01-10 2009-08-06 Alyssa Panitch Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
US20090194105A1 (en) * 2006-04-13 2009-08-06 Jens Besseler Inhaler
US20090230130A1 (en) * 2003-06-09 2009-09-17 John Gelardi System for storing and unpacking encased article
US20090275605A1 (en) * 2005-08-05 2009-11-05 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease
US20090291894A1 (en) * 2005-09-07 2009-11-26 Nikolaos Tezapsidis Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US20100055133A1 (en) * 2008-08-12 2010-03-04 Biovail Laboratories International (Barbados) S.R.L Pharmaceutical compositions
US20100063157A1 (en) * 2004-04-02 2010-03-11 Caine Darren Michael Chemical process and new crystalline form
US7677411B2 (en) 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
WO2010036839A2 (en) * 2008-09-26 2010-04-01 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US20100087476A1 (en) * 2008-09-08 2010-04-08 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US20100087475A1 (en) * 2008-09-08 2010-04-08 Biovali Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
US20100113358A1 (en) * 2005-09-07 2010-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US20100158968A1 (en) * 2008-12-10 2010-06-24 Alyssa Panitch Cell-permeant peptide-based inhibitor of kinases
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
CN101945682A (en) * 2008-02-12 2011-01-12 阿斯利康(瑞典)有限公司 Inhaler comprising a base having at least one sealed cavity containing medicament
US20110052658A1 (en) * 2009-07-27 2011-03-03 Alyssa Panitch Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110061652A1 (en) * 2004-10-21 2011-03-17 Boehringer Ingelheim International Gmbh Blister for inhalers
USD635246S1 (en) 2010-03-26 2011-03-29 Oriel Therapeutics, Inc. Dose disk for dry powder inhalers
US7956065B2 (en) 2008-09-08 2011-06-07 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
USD641076S1 (en) 2010-03-26 2011-07-05 Oriel Therapeutics, Inc. Dry powder inhaler
US20110162648A1 (en) * 2008-09-26 2011-07-07 Ruckdeschel Thomas W Inhaler mechanisms with radially biased piercers and related methods
US20110174306A1 (en) * 2008-09-30 2011-07-21 David Harris Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods
US20110190217A1 (en) * 2005-04-29 2011-08-04 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides
US20110190333A1 (en) * 2008-06-13 2011-08-04 Biovail Laboratories International (Barbados) S.R.L. Dihydrotetrabenanzine for the treatment of anxiety
US20110186047A1 (en) * 2008-10-01 2011-08-04 Scott Alexander Lewis Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods
US20110272427A1 (en) * 2010-05-07 2011-11-10 Fily Sebastien Lucien Blister dispenser
CN102303772A (en) * 2011-06-22 2012-01-04 美的集团有限公司 Automatic adding device for household appliance
WO2012028662A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2436686A1 (en) 2005-03-25 2012-04-04 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
US20120241451A1 (en) * 2011-03-24 2012-09-27 Fred Pether Tamper Device
WO2012159103A1 (en) 2011-05-19 2012-11-22 Savara, Inc. Dry powder vancomycin compositions and associated methods
US8381721B2 (en) 2008-09-26 2013-02-26 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and related devices and methods
EP2589381A1 (en) 2011-11-04 2013-05-08 Rabindra Tirouvanziam Compositions for improving or preserving lung function in a patient with a pulmonary disorder
US20140001194A1 (en) * 2012-06-29 2014-01-02 R. J. Reynolds Tobacco Company Dispensing container, packaged product assembly, and related method
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US8802149B2 (en) 1996-12-31 2014-08-12 Novartis Pharma Ag Systems and processes for spray drying hydrophobic and hydrophilic components
US8875892B1 (en) 2013-03-11 2014-11-04 Dominique Warner Multi-compartment ring-shaped holder
WO2015038644A2 (en) 2013-09-10 2015-03-19 Debrabander Jef Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
WO2015097662A1 (en) * 2013-12-23 2015-07-02 Glenmark Pharmaceuticals Ltd A dry powder inhaler
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
WO2016081475A1 (en) 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2016092378A1 (en) 2014-12-10 2016-06-16 Angelo Luigi Vescovi Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
WO2016200694A1 (en) 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2016203400A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2017011215A1 (en) 2015-07-15 2017-01-19 The Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
US9642888B2 (en) 2011-04-12 2017-05-09 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
USD793356S1 (en) * 2014-12-16 2017-08-01 Musik, LLC Headphone touchpad
EP3202399A1 (en) 2009-07-24 2017-08-09 Amazetis SA Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055524A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018104766A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
US9999655B2 (en) 2015-03-12 2018-06-19 Moerae Matrix, Inc. Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2018109649A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
WO2018109648A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
US20180236188A1 (en) * 2015-10-23 2018-08-23 Arven Ilac Sanayi Ve Ticaret A.S. Blister for inhalable formulation of tiotropium bromide
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
US10087225B2 (en) 2015-01-08 2018-10-02 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
US10112948B2 (en) 2015-07-06 2018-10-30 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
WO2018200425A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019115640A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Intellectual Property Development Limited 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors
US10328216B2 (en) 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
WO2019141694A1 (en) 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiiibeta inhibitors
WO2019224667A1 (en) 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Indanes as nrf2 activators
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020055858A1 (en) 2018-09-10 2020-03-19 Cocrystal Pharma, Inc. Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
WO2020081751A1 (en) 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
WO2020102270A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2020249652A1 (en) 2019-06-13 2020-12-17 Glaxosmithkline Intellectual Property Development Limited Pyridyl or pyrimidyl mtor kinase inhibitors
EP3782996A1 (en) 2015-06-15 2021-02-24 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
WO2021206876A1 (en) 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2023014758A1 (en) 2021-08-03 2023-02-09 Cocrystal Pharma, Inc. Inhibitors for coronaviruses
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
GB925927A (en) * 1960-07-05 1963-05-15 American Cyanamid Co Method and machine for manufacturing plastic granule-containing capsules
GB1019963A (en) * 1961-11-04 1966-02-09 Bodet Jean Augustin A package of pellets and apparatus for producing same
GB1075679A (en) * 1963-11-12 1967-07-12 Ciba Ltd Dispensing container for medicaments
GB1387959A (en) * 1972-06-21 1975-03-19 Sic Schweizerische Ind Ges Apparatus for dividing stacked articles into batches
US4015717A (en) * 1974-03-29 1977-04-05 The Medical Dispenser Company Tablet package for use in chronologically dispensing tablets
US4074806A (en) * 1977-02-18 1978-02-21 Deena Packaging Industries, Inc. Tablet dispensing container
US4089415A (en) * 1975-08-15 1978-05-16 Laib Jakob C Ampule
US4298125A (en) * 1980-05-19 1981-11-03 Bristol-Myers Company Dial type child resistant dispenser
US4342395A (en) * 1981-02-02 1982-08-03 Brown James B Liquid dispensing unit and method of manufacture thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
GB925927A (en) * 1960-07-05 1963-05-15 American Cyanamid Co Method and machine for manufacturing plastic granule-containing capsules
GB1019963A (en) * 1961-11-04 1966-02-09 Bodet Jean Augustin A package of pellets and apparatus for producing same
GB1075679A (en) * 1963-11-12 1967-07-12 Ciba Ltd Dispensing container for medicaments
GB1387959A (en) * 1972-06-21 1975-03-19 Sic Schweizerische Ind Ges Apparatus for dividing stacked articles into batches
US4015717A (en) * 1974-03-29 1977-04-05 The Medical Dispenser Company Tablet package for use in chronologically dispensing tablets
US4089415A (en) * 1975-08-15 1978-05-16 Laib Jakob C Ampule
US4074806A (en) * 1977-02-18 1978-02-21 Deena Packaging Industries, Inc. Tablet dispensing container
US4298125A (en) * 1980-05-19 1981-11-03 Bristol-Myers Company Dial type child resistant dispenser
US4342395A (en) * 1981-02-02 1982-08-03 Brown James B Liquid dispensing unit and method of manufacture thereof

Cited By (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009561A (en) * 1989-08-18 1991-04-23 Pharmacia Diagnostics Inc. Reagent tablet dispenser
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
USRE40045E1 (en) * 1989-09-08 2008-02-05 Glaxo Group Limited Medicaments
US20040250812A1 (en) * 1990-03-02 2004-12-16 Davies Michael Birsha Inhalation device
US7225808B2 (en) 1990-03-02 2007-06-05 Glaxo Group Limited Inhalation device
US20060107948A9 (en) * 1990-03-02 2006-05-25 Davies Michael B Inhalation device
US5492112A (en) * 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US20050279349A1 (en) * 1991-07-02 2005-12-22 Patton John S Method and device for delivering aerosolized medicaments
US5715810A (en) * 1991-07-25 1998-02-10 Sepracor Inc. Inhalation devices
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5529059A (en) * 1991-08-01 1996-06-25 Sepracor Inc. Inhalation devices
US5348158A (en) * 1991-12-19 1994-09-20 G. D. Searle & Co. Dispenser pack for the successive dispensing of a drug
US20030198601A1 (en) * 1992-07-08 2003-10-23 Platz Robert M. Compositions and methods for the pulmonary delivery of aerosolized medicaments
US20030185765A1 (en) * 1992-07-08 2003-10-02 Platz Robert M. Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
US6797258B2 (en) 1992-07-08 2004-09-28 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized macromolecules
US6921527B2 (en) 1992-07-08 2005-07-26 Nektar Therapeutics Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
US5853101A (en) * 1993-01-21 1998-12-29 Primary Delivery Systems, Inc. Blister pack opener
US5431283A (en) * 1993-01-21 1995-07-11 Primary Delivery Systems, Inc. Blister pack opener-ejector
US5356010A (en) * 1993-01-21 1994-10-18 Primary Delivery Systems, Inc. Container with blister pack opener
US7278419B2 (en) 1993-01-29 2007-10-09 Novo Nordisk A/S Method for treating diabetes mellitus in a patient
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6881200B2 (en) 1993-04-08 2005-04-19 Powderject Research Limited Needleless syringe using super sonic gas flow for particle delivery
US7618394B2 (en) 1993-04-08 2009-11-17 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US20050165348A1 (en) * 1993-04-08 2005-07-28 Bellhouse Brian J. Needleless syringe using supersonic gas flow for particle delivery
US7942846B2 (en) 1993-04-08 2011-05-17 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5277328A (en) * 1993-05-24 1994-01-11 Tocco Gary A Multiply compartmented cooler
US5464118A (en) * 1993-08-11 1995-11-07 Hoechst Aktiengesellschaft Apparatus for removing solid medications from blister packs
US6737045B2 (en) 1994-03-07 2004-05-18 Nektar Therapeutics Methods and compositions for the pulmonary delivery insulin
US7521069B2 (en) 1994-03-07 2009-04-21 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US6543448B1 (en) 1994-09-21 2003-04-08 Inhale Therapeutic Systems, Inc. Apparatus and methods for dispersing dry powder medicaments
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US7785631B2 (en) 1994-12-02 2010-08-31 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7780991B2 (en) 1994-12-02 2010-08-24 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7097827B2 (en) 1995-04-14 2006-08-29 Inhale Therapeutic Systems, Inc. Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
WO1996033759A1 (en) * 1995-04-24 1996-10-31 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
EP0835147B1 (en) * 1995-04-24 2004-01-28 Valois SAS Dry powder inhaler delivery system
US6029663A (en) * 1995-04-24 2000-02-29 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5921237A (en) * 1995-04-24 1999-07-13 Dura Pharmaceuticals, Inc. Dry powder inhaler
EP0835147A1 (en) * 1995-04-24 1998-04-15 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5622166A (en) * 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US6672304B1 (en) 1995-06-08 2004-01-06 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIs)
US6729324B2 (en) 1995-06-08 2004-05-04 Innovative Devices, Llc. Inhalation actuated device for use with metered dose inhalers (MDIs)
US20040237961A1 (en) * 1995-06-08 2004-12-02 Snow John Medlin Inhalation actuated device for use with metered dose inhalers (MDIs)
US6550477B1 (en) 1995-08-02 2003-04-22 Innovative Devices, Llc Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US6561186B2 (en) 1995-08-02 2003-05-13 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5816404A (en) * 1996-02-20 1998-10-06 Seidler; David Blister pack with built-in openers
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5857456A (en) * 1996-06-10 1999-01-12 Sarnoff Corporation Inhaler apparatus with an electronic means for enhanced release of dry powders
US6591833B2 (en) 1996-06-10 2003-07-15 Delsys Pharmaceutical Corp. Inhaler apparatus with modified surfaces for enhanced release of dry powders
US5964417A (en) * 1996-11-20 1999-10-12 Ing. Erich Pfeiffer Gmbh Dispenser for discharging media
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US8802149B2 (en) 1996-12-31 2014-08-12 Novartis Pharma Ag Systems and processes for spray drying hydrophobic and hydrophilic components
US6367473B1 (en) * 1997-02-08 2002-04-09 Ing. Erich Pfeiffer Gmbh Medium dispenser
US5909822A (en) * 1997-05-03 1999-06-08 George; Donald C. Pill dispenser employing a sealed pill carrier
US5915560A (en) * 1997-05-03 1999-06-29 George; Donald C. Compartmentalized pill dispenser
US6116238A (en) * 1997-12-02 2000-09-12 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6655379B2 (en) 1998-03-16 2003-12-02 Nektar Therapeutics Aerosolized active agent delivery
US7422013B2 (en) 1998-06-04 2008-09-09 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US20080230058A1 (en) * 1998-06-04 2008-09-25 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US8161969B2 (en) 1998-06-04 2012-04-24 Novartis Ag Dry powder dispersing apparatus and methods for their use
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US20030209243A1 (en) * 1998-06-04 2003-11-13 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6901929B2 (en) 1998-06-04 2005-06-07 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US6546929B2 (en) 1998-06-04 2003-04-15 Inhale Therapeutic Systems, Inc. Dry powder dispersing apparatus and methods for their use
US6098835A (en) * 1998-09-03 2000-08-08 Valley Design Inc. Child resistant pill rotating disk dispenser
US8408200B2 (en) 1998-10-09 2013-04-02 Novartis Ag Flow resistance modulated aerosolized active agent delivery
US20020168322A1 (en) * 1998-10-09 2002-11-14 Andrew Clark Flow resistance modulated aerosolized active agent delivery
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6915802B1 (en) * 1999-10-16 2005-07-12 Smithkline Beecham Corporation Medicament pack
US6810872B1 (en) * 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US20050048003A1 (en) * 1999-12-10 2005-03-03 Unisia Jecs Corporation Inhalant medicator
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US6443307B1 (en) 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
WO2001085097A3 (en) * 2000-05-10 2002-07-25 Innovative Devices Llc Medicament container with same side airflow inlet and outlet and method of use
US20020134382A1 (en) * 2000-05-10 2002-09-26 Snow John M. Medicament container with same side airflow inlet and outlet and method of use
WO2001085097A2 (en) * 2000-05-10 2001-11-15 Innovative Devices, Llc Medicament container with same side airflow inlet and outlet and method of use
EP1726324A1 (en) 2000-05-10 2006-11-29 Innovative Devices, LLC Medicament container with same side airflow inlet and outlet
US20050056281A1 (en) * 2000-05-10 2005-03-17 Snow John M. Medicament container with same side airflow inlet and outlet and method of use
JP2004508072A (en) * 2000-05-10 2004-03-18 イノベーティブ・ディバイシィーズ・エルエルシー Drug container with airflow inlet and outlet on the same side, and method of using the container
US7318436B2 (en) 2000-05-10 2008-01-15 Innovative Devices, Llc Medicament container with same side airflow inlet and outlet and method of use
EP1283731A2 (en) * 2000-05-10 2003-02-19 Innovative Devices, LLC Medicament container with same side airflow inlet and outlet and method of use
JP4754758B2 (en) * 2000-05-10 2011-08-24 イノベーティブ・ディバイシィーズ・エルエルシー Drug container with air flow inlet and outlet on the same side
US6923178B2 (en) 2000-05-10 2005-08-02 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet
EP1283731A4 (en) * 2000-05-10 2004-06-23 Innovative Devices Llc Medicament container with same side airflow inlet and outlet and method of use
US6948494B1 (en) 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
AU2001249773B2 (en) * 2000-05-10 2005-10-13 Zhejiang Hisun Pharmaceutical Co., Ltd. Medicament container with same side airflow inlet and outlet and method of use
US20050161041A1 (en) * 2000-05-16 2005-07-28 Carlos Schuler Systems devices and methods for opening receptacles having a powder to be fluidized
US7814905B2 (en) * 2000-05-16 2010-10-19 Novartis Ag Systems devices and methods for opening receptacles having a powder to be fluidized
US6669022B2 (en) * 2001-03-20 2003-12-30 Comar, Inc. Rotatable compact case with non-removable pill package insert
WO2002098495A1 (en) 2001-06-07 2002-12-12 Innovata Biomed Limited Unit dosage powder container
US8061006B2 (en) 2001-07-26 2011-11-22 Powderject Research Limited Particle cassette, method and kit therefor
US20080300535A1 (en) * 2001-07-26 2008-12-04 Powderject Research Limited Particle cassette, method and kit therefor
US6871647B2 (en) 2001-09-19 2005-03-29 Advent Pharmaceuticals Pty Ltd Inhaler
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030075172A1 (en) * 2001-10-19 2003-04-24 Johnson Keith A. Method and apparatus for dispensing inhalator medicament
US9636471B2 (en) 2002-01-25 2017-05-02 Glaxo Group Limited Medicament dispenser
US20050154491A1 (en) * 2002-01-25 2005-07-14 Anderson Gregor J.M. Medicament dispenser
US8511304B2 (en) 2002-01-25 2013-08-20 Glaxo Group Limited Medicament dispenser
US20060187750A1 (en) * 2002-03-01 2006-08-24 Victor Aldrich Rotary blending apparatus and system
US20050236420A1 (en) * 2002-03-06 2005-10-27 Reckitt Benckiser N.V. Container
WO2003080469A1 (en) * 2002-03-19 2003-10-02 Comar, Inc. Rotatable compact case with non-removable pill package insert
US20050103678A1 (en) * 2002-03-26 2005-05-19 Clark Verna L. Method for forming a laminate assembly and products formed thereby
US7448184B2 (en) 2002-03-26 2008-11-11 Glaxo Group Limited Method for forming a laminate assembly with an ultrasonic welder
US7271197B2 (en) 2002-04-25 2007-09-18 Glaxo Group Limited Phenethanolamine derivatives
US20050256201A1 (en) * 2002-04-25 2005-11-17 Glaxo Group Limited Phenethanolamine derivatives
US20060050765A1 (en) * 2002-04-25 2006-03-09 Walker Dwight S Magnetoacoustic sensor system and associated method for sensing environmental conditions
US7429127B2 (en) 2002-04-25 2008-09-30 Glaxo Group Limited Magnetoacoustic sensor system and associated method for sensing environmental conditions
US20090165790A1 (en) * 2002-05-10 2009-07-02 Oriel Therapeutics, Inc. Dry powder inhalers
US8210172B2 (en) 2002-05-10 2012-07-03 Oriel Therapeutics, Inc. Dry powder inhalers
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US7520278B2 (en) 2002-05-10 2009-04-21 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US7677411B2 (en) 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US20040153262A1 (en) * 2002-05-10 2004-08-05 Crowder Timothy M. Dry powder dose filling systems and related methods
WO2003095010A2 (en) * 2002-05-10 2003-11-20 Oriel Therapeutics, Inc. Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material
US20040050860A1 (en) * 2002-05-10 2004-03-18 Crowder Timothy M. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
WO2003095010A3 (en) * 2002-05-10 2004-03-18 Oriel Therapeutics Inc Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material
US7428446B2 (en) 2002-05-10 2008-09-23 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
US7089786B2 (en) 2002-05-15 2006-08-15 Glaxo Group Limited Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging
WO2003107397A2 (en) * 2002-05-15 2003-12-24 Glaxo Group Limited Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging
WO2003107397A3 (en) * 2002-05-15 2004-02-26 Glaxo Group Ltd Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging
US20050223827A1 (en) * 2002-05-15 2005-10-13 Walker Dwight S Microelectromechanical system and method for determning temperature and moisture profiles within pharmaceutical packaging
US7185651B2 (en) 2002-06-18 2007-03-06 Nektar Therapeutics Flow regulator for aerosol drug delivery and methods
US20040000309A1 (en) * 2002-06-18 2004-01-01 William Alston Flow regulator for aerosol drug delivery and methods
US20050268908A1 (en) * 2002-07-25 2005-12-08 Bonney Stanley G Medicament dispenser
US20050268909A1 (en) * 2002-07-25 2005-12-08 Bonney Stanley G Medicament dispenser
US20050274378A1 (en) * 2002-07-25 2005-12-15 Bonney Stanley G Medicament dispenser
US20050251289A1 (en) * 2002-07-25 2005-11-10 Bonney Stanley G Medicament dispenser
US20050247312A1 (en) * 2002-07-25 2005-11-10 Davies Michael B Medicament dispenser
US20070267318A1 (en) * 2002-08-29 2007-11-22 Colbert Packaging Corporation Dispensing Package
US7784250B2 (en) 2002-08-29 2010-08-31 Colbert Packaging Corporation Method of forming childproof blister pack
US7748535B2 (en) * 2002-08-29 2010-07-06 Colbert Packaging Corporation Dispensing package
US20080223747A1 (en) * 2002-08-29 2008-09-18 Colbert Packaging Corporation Childproof, senior-friendly blister pack
US20070139442A1 (en) * 2002-09-13 2007-06-21 Robinson Karl E Coated blending system
US20060205790A1 (en) * 2002-10-22 2006-09-14 Coe Diane M Medicinal arylethanolamine compounds
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
US20060076010A1 (en) * 2002-12-18 2006-04-13 King Michael L Drug delivery system with vented mouthpiece
US20050252510A1 (en) * 2002-12-18 2005-11-17 Quadrant Technologies Limited Unit dose dry powder inhaler
US6941947B2 (en) 2002-12-18 2005-09-13 Quadrant Technologies Limited Unit dose dry powder inhaler
WO2004054646A1 (en) 2002-12-18 2004-07-01 Quadrant Technologies Limited Unit dose dry powder inhaler
US20040118399A1 (en) * 2002-12-18 2004-06-24 Elan Pharmaceutical Technologies Unit dose dry powder inhaler
US20040173211A1 (en) * 2003-01-14 2004-09-09 Boehringer Ingelheim International Gmbh Powder inhaler
US20060148771A1 (en) * 2003-02-14 2006-07-06 Keith Biggadike Medicinal compounds
US7538127B2 (en) 2003-02-14 2009-05-26 Glaxo Group Limited Medicinal compounds
US20090230130A1 (en) * 2003-06-09 2009-09-17 John Gelardi System for storing and unpacking encased article
US20060237010A1 (en) * 2003-06-16 2006-10-26 Rijksuniversiteit Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US7617822B2 (en) 2003-06-16 2009-11-17 Rijksuniversiteit Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US20090105309A1 (en) * 2003-10-22 2009-04-23 Glaxo Group Limited Medicinal Compounds
US20070135490A1 (en) * 2003-10-24 2007-06-14 Keith Biggadike Phenetanolamine derivatives
US7451761B2 (en) 2003-10-27 2008-11-18 Oriel Therapeutics, Inc. Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances
US7377277B2 (en) 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
US20070277820A1 (en) * 2003-10-27 2007-12-06 Timothy Crowder Blister packages and associated methods of fabricating dry powder drug containment systems
US20070053843A1 (en) * 2003-10-28 2007-03-08 Dawson Michelle L Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
US7294650B2 (en) 2003-12-17 2007-11-13 Glaxo Group Limited Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders
US20070172385A1 (en) * 2003-12-17 2007-07-26 Glaxo Group Limited Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders
US20050143675A1 (en) * 2003-12-31 2005-06-30 Home Diagnostics, Inc. Integrated diagnostic test system
US20080108645A1 (en) * 2004-02-11 2008-05-08 Cambridge Laboratories, (Ireland), Ltd. Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
US7159720B2 (en) 2004-03-18 2007-01-09 Pearson Stephen J Container having a rotatable ring
US7846973B2 (en) 2004-04-02 2010-12-07 Theravance, Inc. Chemical process and new crystalline form
US20100063157A1 (en) * 2004-04-02 2010-03-11 Caine Darren Michael Chemical process and new crystalline form
US20050238708A1 (en) * 2004-04-23 2005-10-27 Andrew Jones Sealed capsule including an integrated puncturing mechanism
US7861712B2 (en) 2004-04-23 2011-01-04 Manta Product Development Sealed capsule including an integrated puncturing mechanism
US20060005398A1 (en) * 2004-07-12 2006-01-12 Steve Sramek Device for removing a pharmaceutical dosage unit from a unit package
US20110061652A1 (en) * 2004-10-21 2011-03-17 Boehringer Ingelheim International Gmbh Blister for inhalers
US20080042823A1 (en) * 2004-11-12 2008-02-21 Heasley Matthew G Sensor System with Acoustic Transducer
US20080125462A1 (en) * 2005-01-11 2008-05-29 Lois Elizabeth Vernon Cinnamate Salts Of A Beta-2 Adrenergic Agonist
US20090047351A1 (en) * 2005-02-10 2009-02-19 Stephen Newman Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom
US20090029901A1 (en) * 2005-02-10 2009-01-29 Marian Wood-Kaczmar Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations
US9365905B2 (en) 2005-02-10 2016-06-14 Dmv-Fonterra Excipients Technology Gmbh Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP3199164A1 (en) 2005-02-10 2017-08-02 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
US20090057186A1 (en) * 2005-02-15 2009-03-05 Willard Rick L Pill packaging system
EP2436686A1 (en) 2005-03-25 2012-04-04 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
WO2006104889A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Novel compounds
EP2447266A1 (en) 2005-03-25 2012-05-02 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US10047132B2 (en) 2005-04-29 2018-08-14 Peter C. Dowling Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US10010583B2 (en) 2005-04-29 2018-07-03 Peter C. Dowling Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US20110190217A1 (en) * 2005-04-29 2011-08-04 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides
US20090029906A1 (en) * 2005-04-29 2009-01-29 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9765128B2 (en) 2005-04-29 2017-09-19 Peter C. Dowling Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US11559565B2 (en) 2005-04-29 2023-01-24 United States Government As Represented By The Department Of Veterans Affairs Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US20080319000A1 (en) * 2005-07-14 2008-12-25 Cambridge Laboratories (Ireland) Limited Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease
US20080197045A1 (en) * 2005-07-27 2008-08-21 Burkhard Metzger Medicament Blister
US9168342B2 (en) * 2005-07-27 2015-10-27 Boehringer Ingelheim International Gmbh Medicament blister
US20090275605A1 (en) * 2005-08-05 2009-11-05 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease
US20090192227A1 (en) * 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis
US20090291894A1 (en) * 2005-09-07 2009-11-26 Nikolaos Tezapsidis Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US20100113358A1 (en) * 2005-09-07 2010-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US20070066527A1 (en) * 2005-09-07 2007-03-22 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US7891100B2 (en) 2006-01-03 2011-02-22 Meadwestvaco Corporation System for opening an article encasement
US20070164029A1 (en) * 2006-01-03 2007-07-19 Gelardi John A System for Opening an Article Encasement
US20090194105A1 (en) * 2006-04-13 2009-08-06 Jens Besseler Inhaler
US8584669B2 (en) * 2006-04-13 2013-11-19 Boehringer Ingelheim International Gmbh Inhaler
WO2008037519A1 (en) * 2006-09-26 2008-04-03 Alfred Von Schuckmann Dispenser for powder compounds
EP2100634A3 (en) * 2006-09-26 2009-09-23 von Schuckmann, Alfred Dispenser for powder compounds
EP2100634A2 (en) 2006-09-26 2009-09-16 von Schuckmann, Alfred Dispenser for powder compounds
US8434476B2 (en) * 2006-09-26 2013-05-07 Alfred Von Schuckmann Dispenser for pulverulent substances
US20100083962A1 (en) * 2006-09-26 2010-04-08 Alfred Von Schuckmann Dispenser for pulverulent substances
US20080156816A1 (en) * 2007-01-03 2008-07-03 Gelardi John A Container With Cutting Apparatus
US20090196927A1 (en) * 2007-01-10 2009-08-06 Alyssa Panitch Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
US9447158B2 (en) 2007-01-10 2016-09-20 Purdue Research Foundation Kinase inhibitors and uses thereof
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
US8536303B2 (en) 2007-01-10 2013-09-17 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
US20090149389A1 (en) * 2007-01-10 2009-06-11 Purdue Research Foundation Kinase Inhibitors And Uses Thereof
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
US9649354B2 (en) 2007-01-10 2017-05-16 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therfor
US9034815B2 (en) 2007-01-10 2015-05-19 Moerae Matrix, Inc Polypeptide for treating or preventing adhesions
US9493508B2 (en) 2007-01-10 2016-11-15 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US20080237082A1 (en) * 2007-03-29 2008-10-02 R. P. Scherer Technologies, Inc. Child resistant device for housing blister packs
WO2009004456A1 (en) * 2007-07-02 2009-01-08 Pfizer Limited Dry powder container and use of such dry powder container in a dry powder inhaler
CN101945682A (en) * 2008-02-12 2011-01-12 阿斯利康(瑞典)有限公司 Inhaler comprising a base having at least one sealed cavity containing medicament
US9174011B2 (en) 2008-02-12 2015-11-03 Astrazeneca Ab Inhaler comprising a base having a plurality of medicament containing sealed cavities
CN101945682B (en) * 2008-02-12 2013-12-04 阿斯利康(瑞典)有限公司 Inhaler comprising a base having at least one sealed cavity containing medicament
US20110190333A1 (en) * 2008-06-13 2011-08-04 Biovail Laboratories International (Barbados) S.R.L. Dihydrotetrabenanzine for the treatment of anxiety
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20100055133A1 (en) * 2008-08-12 2010-03-04 Biovail Laboratories International (Barbados) S.R.L Pharmaceutical compositions
US20100087476A1 (en) * 2008-09-08 2010-04-08 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US20100087475A1 (en) * 2008-09-08 2010-04-08 Biovali Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US7956065B2 (en) 2008-09-08 2011-06-07 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US8671938B2 (en) 2008-09-26 2014-03-18 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US8381721B2 (en) 2008-09-26 2013-02-26 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and related devices and methods
US20100078022A1 (en) * 2008-09-26 2010-04-01 Rachel Striebig Inhalers with airway disks having discrete airway channels and related disks and methods
US9597465B2 (en) 2008-09-26 2017-03-21 Oriel Therapeutics, Inc. Methods of operating and fabricating inhalers with airway disks having discrete airway channels
US9795749B2 (en) 2008-09-26 2017-10-24 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and methods of operating same
US8550071B2 (en) 2008-09-26 2013-10-08 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US20110162648A1 (en) * 2008-09-26 2011-07-07 Ruckdeschel Thomas W Inhaler mechanisms with radially biased piercers and related methods
WO2010036839A2 (en) * 2008-09-26 2010-04-01 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US8985103B2 (en) 2008-09-26 2015-03-24 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members
US10493222B2 (en) 2008-09-26 2019-12-03 Oriel Therapeutics, Inc. Dry powder dose container assemblies and related inhalers
US8887722B2 (en) 2008-09-26 2014-11-18 Oriel Therapeutics, Inc. Inhaler mechanisms with radially biased piercers and related methods
WO2010036839A3 (en) * 2008-09-26 2010-06-03 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US9050427B2 (en) 2008-09-30 2015-06-09 Oriel Therapeutics, Inc. Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods
US20110174306A1 (en) * 2008-09-30 2011-07-21 David Harris Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods
US20110186047A1 (en) * 2008-10-01 2011-08-04 Scott Alexander Lewis Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods
US8646446B2 (en) 2008-10-01 2014-02-11 Oriel Therapeutics, Inc. Dry powder inhalers with rotating piercing mechanisms and related devices and methods
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20100158968A1 (en) * 2008-12-10 2010-06-24 Alyssa Panitch Cell-permeant peptide-based inhibitor of kinases
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP3202399A1 (en) 2009-07-24 2017-08-09 Amazetis SA Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110052658A1 (en) * 2009-07-27 2011-03-03 Alyssa Panitch Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
USD685461S1 (en) 2010-03-26 2013-07-02 Oriel Therapeutics, Inc. Dose disk for a dry powder inhaler
USD635246S1 (en) 2010-03-26 2011-03-29 Oriel Therapeutics, Inc. Dose disk for dry powder inhalers
USD711528S1 (en) 2010-03-26 2014-08-19 Oriel Therapeutics, Inc. Dry powder inhaler
USD745660S1 (en) 2010-03-26 2015-12-15 Oriel Therapeutics, Inc. Dry powder inhaler
USD641076S1 (en) 2010-03-26 2011-07-05 Oriel Therapeutics, Inc. Dry powder inhaler
USD684684S1 (en) 2010-03-26 2013-06-18 Oriel Therapeutics, Inc. Dry powder inhaler
US20110272427A1 (en) * 2010-05-07 2011-11-10 Fily Sebastien Lucien Blister dispenser
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2954888A1 (en) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012028662A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
US20120241451A1 (en) * 2011-03-24 2012-09-27 Fred Pether Tamper Device
US8579116B2 (en) * 2011-03-24 2013-11-12 Oneworld Design and Manufacturing Group, Ltd. Tamper evident device
US10562947B2 (en) 2011-04-12 2020-02-18 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9642888B2 (en) 2011-04-12 2017-05-09 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2012159103A1 (en) 2011-05-19 2012-11-22 Savara, Inc. Dry powder vancomycin compositions and associated methods
CN102303772A (en) * 2011-06-22 2012-01-04 美的集团有限公司 Automatic adding device for household appliance
CN102303772B (en) * 2011-06-22 2013-05-08 美的集团股份有限公司 Automatic adding device for household appliance
EP2589381A1 (en) 2011-11-04 2013-05-08 Rabindra Tirouvanziam Compositions for improving or preserving lung function in a patient with a pulmonary disorder
US10034839B2 (en) 2012-03-09 2018-07-31 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US9493291B2 (en) 2012-06-29 2016-11-15 R. J. Reynolds Tobacco Company Dispensing container, packaged product assembly, and related method
US9108784B2 (en) * 2012-06-29 2015-08-18 R.J. Reynolds Tobacco Company Dispensing container, packaged product assembly, and related method
US20140001194A1 (en) * 2012-06-29 2014-01-02 R. J. Reynolds Tobacco Company Dispensing container, packaged product assembly, and related method
US11291644B2 (en) 2012-09-04 2022-04-05 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US8875892B1 (en) 2013-03-11 2014-11-04 Dominique Warner Multi-compartment ring-shaped holder
WO2015038644A2 (en) 2013-09-10 2015-03-19 Debrabander Jef Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
US9856233B2 (en) 2013-09-10 2018-01-02 Board Of Regents Of The University Of Texas System Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
US10577344B2 (en) 2013-09-10 2020-03-03 The Board Of Regents Of The University Of Texas System Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
EA034279B1 (en) * 2013-12-23 2020-01-24 Гленмарк Фармасьютикалс Лтд Dry powder inhaler
WO2015097662A1 (en) * 2013-12-23 2015-07-02 Glenmark Pharmaceuticals Ltd A dry powder inhaler
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
WO2016081475A1 (en) 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10500249B2 (en) 2014-11-17 2019-12-10 Moerae Matrix Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US11357840B2 (en) 2014-12-10 2022-06-14 Hyperstem Sa Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
US10688167B2 (en) 2014-12-10 2020-06-23 Hyperstem Sa Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
WO2016092378A1 (en) 2014-12-10 2016-06-16 Angelo Luigi Vescovi Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
USD857650S1 (en) 2014-12-16 2019-08-27 Muzik Inc. Touchpad
USD793356S1 (en) * 2014-12-16 2017-08-01 Musik, LLC Headphone touchpad
US10087225B2 (en) 2015-01-08 2018-10-02 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
US9999655B2 (en) 2015-03-12 2018-06-19 Moerae Matrix, Inc. Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
WO2016200694A1 (en) 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
EP3766878A1 (en) 2015-06-15 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
EP3782996A1 (en) 2015-06-15 2021-02-24 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2016203400A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US11548894B2 (en) 2015-07-06 2023-01-10 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
US10112948B2 (en) 2015-07-06 2018-10-30 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
WO2017011215A1 (en) 2015-07-15 2017-01-19 The Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
US20180236188A1 (en) * 2015-10-23 2018-08-23 Arven Ilac Sanayi Ve Ticaret A.S. Blister for inhalable formulation of tiotropium bromide
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US10328216B2 (en) 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
WO2018055524A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018104766A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018109648A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2018109649A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
WO2018200425A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
US11014941B2 (en) 2017-04-24 2021-05-25 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019115640A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Intellectual Property Development Limited 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors
WO2019141694A1 (en) 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiiibeta inhibitors
WO2019224667A1 (en) 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Indanes as nrf2 activators
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020055858A1 (en) 2018-09-10 2020-03-19 Cocrystal Pharma, Inc. Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
WO2020081751A1 (en) 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
WO2020102270A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2020249652A1 (en) 2019-06-13 2020-12-17 Glaxosmithkline Intellectual Property Development Limited Pyridyl or pyrimidyl mtor kinase inhibitors
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
WO2021206876A1 (en) 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2023014758A1 (en) 2021-08-03 2023-02-09 Cocrystal Pharma, Inc. Inhibitors for coronaviruses

Similar Documents

Publication Publication Date Title
US4778054A (en) Pack for administering medicaments to patients
US4627432A (en) Devices for administering medicaments to patients
GB2169265A (en) Pack for medicament
JP4044620B2 (en) System for administration by inhalation of powdered drugs
EP0835147B1 (en) Dry powder inhaler delivery system
EP0883414B1 (en) Inhalation device
FI88112B (en) ANORDNING FOER ADMINISTRERING AV LAEKEMEDEL TILL PATIENTER
EP0469814A1 (en) Medicament administering devices
EP0481666A1 (en) Powder inhaler device
EP2731571B1 (en) Improvements relating to delivery devices
JPH08501046A (en) Drug packaging
JPS5988158A (en) Apparatus for dosing drug to patient and pack used therefor
CA1236736A (en) Device for administering medicament to patients
WO2005110519A1 (en) Dry powder inhaler
FI81255C (en) Packaging for use in inhalation device
IE873338L (en) Medicament- containing pack.
DK173079B1 (en) Hand-held inhaler for powder or liq. medical inhalants - which are in dose sized blisters of circular disc blister pack
NL193681C (en) Packaging for medicines.
MXPA99005698A (en) Medicament delivery and packaging

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLAXO GROUP LIMITED, CLARGES HOUSE, 6/12 CLARGES S

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:NEWELL, ROBERT E.;FITZSIMMONS, ROBERT A.;REEL/FRAME:004638/0977;SIGNING DATES FROM 19861103 TO 19861113

Owner name: GLAXO GROUP LIMITED,ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEWELL, ROBERT E.;FITZSIMMONS, ROBERT A.;SIGNING DATES FROM 19861103 TO 19861113;REEL/FRAME:004638/0977

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12